Makers Laboratories profitability ratios

Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
Returns
−3.1%—−12.7%−10.9%
−2.4%—−8.1%−7.5%
−3.1%−6.7%−10.0%−9.1%
Margins
1.5%−5.1%−7.7%−9.7%
−4.1%−11.8%−13.2%−15.4%
40.3%−23.1%0.9%—
−4.0%11.5%−14.2%−15.9%
−3.4%—−14.2%−15.0%
−4.6%−9.3%−11.7%−13.9%
Additional
14.5%—0.1%6.4%
−3.1%—−12.7%−10.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MAKERSL₹187.00

Makers Laboratories Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOCMcap ₹111 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Returns
Return on Common Equity-10.91-12.67—-3.11
Return on Assets-7.50-8.13—-2.37
Return on Invested Capital-9.06-9.96-6.73-3.10
Margins
EBITDA Margin-9.72-7.66-5.141.45
Operating Margin-15.35-13.19-11.77-4.12
Incremental Operating Margin—0.87-23.1340.28
Pretax Margin-15.93-14.1711.48-3.99
Net Income Margin-14.95-14.16—-3.42
FCF Margin-13.88-11.73-9.34-4.63
Additional
Effective Tax Rate6.350.06—14.49
Sustainable Growth Rate-10.91-12.67—-3.11
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.